Qianjin Pharmaceutical Subsidiaries Obtain Registration Certificates for Four Drugs

财中社··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Qianjin Pharmaceutical announced that its subsidiaries Hunan Qianjin Xiangjiang Pharmaceutical and Hunan Qianjin Xieli Pharmaceutical obtained drug registration certificates for a total of four drugs. The four drugs are minoxidil liniment, ezetimibe tablets, amlodipine benazepril capsules, and ursodeoxycholic acid capsules. Among them, minoxidil liniment is used to stimulate hair growth in patients with hair loss, and Qianjin Xiangjiang Pharmaceutical has invested a cumulative 5.63 million yuan in research and development; ursodeoxycholic acid capsules are used to treat cholesterol gallstones in the gallbladder, and Qianjin Xieli Pharmaceutical has invested a cumulative 9.8 million yuan in research and development. In the first quarter of 2026, Qianjin Pharmaceutical achieved revenue of 970 million yuan and net profit attributable to the parent company of 75 million yuan.

Impact on assets 1

Others▲ · 1 stocks

Off-coverage companies 2

Hunan Qianjin Xieli Pharmaceutical Co., Ltd.Private▲ Positive
Technologyrelevance

Obtained registration certificate for ursodeoxycholic acid capsules and other drugs.

湖南千金湘江药业有限公司Private▲ Positive
Technologyrelevance

Obtained registration certificate for minoxidil liniment and other drugs.

© 2026 MarketIVNews